EGFR Mutations in Patients with Advanced NSCLC

Česká verze

Authors: O. Fiala ¹; M. Pešek ²; J. Fínek ¹; F. Brůha ²; Z. Bortlíček ³; J. Krejčí ⁴; L. Benešová ⁵; M. Minárik ⁵
Authors place of work: Onkologické a radioterapeutické oddělení, FN Plzeň ¹; Klinika TRN, FN Plzeň ²; Institut biostatistiky a analýz, MU Brno ³; Klinika pneumologie a hrudní chirurgie, FN Na Bulovce Praha ⁴; Centrum aplikované genomiky solidních nádorů (CEGES), Genomac výzkumný ústav, Praha ⁵
Published in the journal: Klin Onkol 2012; 25(4): 267-273
Category: Původní práce

Summary

Background:
Molecular targeted therapy based on tyrosine kinase inhibitors, directed at the epidermal growth factor receptor (EGFR) is one of novel options for management of NSCLC. EGFR gene mutations, exon 19 deletions and exon 21 point mutations (L858R) are good predictors of response to EGFR-TKI treatment. The aim of this study was to assess the incidence of EGFR mutations in a large cohort of Europeans with advanced NSCLC and subsequently to evaluate their impact on the effect of EGFR-TKI treatment.

Patients and Methods:
In total, 613 patients with advanced stage NSCLC (IIIB, IV) were genetically tested. The effect of treatment was evaluated in 410 patients treated with EGFR-TKI. Survival was evaluated using Kaplan-Meier method, and statistical comparison was performed using log-rank test.

Results:
EGFR mutations were detected in 73 (11.9%) patients. Exon 19 deletions were detected in 49 patients, exon 21 point mutations (L858R) were detected in 22 patients, and both mutation types were detected in 2 patients. An increased incidence of EGFR mutations among patients with adenocarcinoma (14.9% vs 7.8%, p = 0.008), women (20.2% vs 7.1%, p < 0.001) and nonsmokers (29.9% vs 7.0%, p < 0.001) was demonstrated. Sixty patients with EGFR mutation and 350 patients with wild-type EGFR were treated with EGFR-TKI. Median PFS in patients harboring EGFR mutation was 7.2 vs 2.0 months in patients harboring wild-type EGFR (p < 0.001), median OS in patients harboring EGFR mutation was 14.5 vs 7.5 months in patients harboring wild-type EGFR (p = 0.019).

Conclusion:
The incidence of EGFR mutations in the studied population, their increased incidence among patients with adenocarcinoma, women and non-smokers correlated with data previously published. Results of survival analysis in patients treated with EGFR-TKI confirmed high potential of EGFR mutations to predict good effect of the EGFR-TKI treatment. Genetic testing in patients with NSCLC should be a standard part of diagnostic procedures

Key words:
NSCLC – EGFR gene – EGFR protein – protein kinase inhibitors – EGFR mutation – molecular targeted therapy

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
10. 1. 2012

Accepted:
24. 2. 2012

Zdroje

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129–2139.

2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497–1500.

3. Gandhi J, Zhang J, Xie Y et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009; 4(2): e4576.

4. Minárik M, Benešová L, Belšánová B et al. Vliv mutací genů EGFR a KRAS na prognózu přežití u pacientů s nemalobuněčným karcinomem plic, léčených inhibitory tyrosin-kináz (srovnání výsledků léčby gefitinibem a erlotinibem). Stud Pneumol Phtiseol 2009; 69(3): 96–104.

5. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non--small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23(25): 5900–5909.

6. Bonanno L, Schiavon M, Nardo G et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010; 30(12): 5121–5128.

7. Liu HP, Isaac Wu HD, Chang JW et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non--small cell lung cancer in Taiwan. J Thorac Oncol 2010; 5(8): 1175–1184.

8. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26(26): 4268–4275.

9. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24(31): 5034–5042.

10. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28(5): 744–752.

11. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11(6): 521–529.

12. Brugger W, Triller N, Blasinska-Morawiec M et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first--line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27 (Suppl): 15. Abstract 8020.

13. Pesek M, Benesova L, Belsanova B et al. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009; 29(7): 2767–2773.

14. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28 (Suppl 1): S24–S31.

15. Zhang Z, Stiegler AL, Boggon TJ et al. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010; 1(7): 497–514.

16. Sequist LV, Bell DW, Lynch TJ et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25(5): 587–595.

17. Gandara DR, Lara PN Jr, Mack P et al. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 2009; 10(3): 148–150.

18. West H, Lilenbaum R, Harpole D et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 2009; 4 (9 Suppl 2): S1029–S1039.

19. Forbes SA, Bhamra G, Bamford S et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008; Chapter 10: Unit 10.11.

20. Shukuya T, Takahashi T, Kaira R et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011; 102(5): 1032–1037.

21. Yamamoto H, Shigematsu H, Nomura M et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68(17): 6913–6921.

22. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11(8): 753–762.

23. Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006; 54(2): 209–215.

24. Lee SY, Kim MJ, Jin G et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non--small cell lung cancers. J Thorac Oncol 2010; 5(11): 1734–1740.